| 查看: 220 | 回复: 1 | |||
| 当前主题已经存档。 | |||
[交流]
40 New drugs added since 29 Jun 2007
|
|||
|
TTP-355 Originator: TransTech Pharma Inc. Highest Dev Status: Clinical. Updated on 05 July 2007. TransTech Pharma is developing TTP-355, a glucokinase activator, for the potential treatment of diabetes. By July 2007, the drug was in clinical trials [ 810925 ]. The company is also developing the glucokinase activator NN-9101 .. . Amelior Originator: Cumberland Pharmaceuticals Inc. Highest Dev Status: Phase 3 Clinical. Updated on 05 July 2007. Cumberland Pharmaceuticals is developing Amelior, an injectable formulation of ibuprofen for the potential treatment of pain and fever. By May 2007, phase III trials were underway for both indications [ 803729 ]; at that time, clinical development was expected to be completed by early 2008, and the company was preparing to submit an NDA to the FDA [ 81..... . Cx-401 Originator: Cellerix SL. Highest Dev Status: Phase 3 Clinical. Updated on 04 July 2007. Cellerix is developing expanded autologous adipose-derived stem cells, an injectable therapy referred to as Cx-401, for the potential treatment of complex perianal fistula [ 810536 ]. By February 2007, phase III trials were underway [ 803739 ]; in July 2007, the company expected Cx-401 to reach the market in 2009 or 2010 [ 810550 ]. By July 2007, the..... . rifamycin SV MMX Originator: Cosmo Pharmaceuticals SpA. Highest Dev Status: Phase 3 Clinical. Updated on 06 July 2007. Cosmo Pharmaceuticals is developing rifamycin SV MMX (CB-01-11) an oral controlled release, gastro-intestinal site-specific rifamycin antibiotic, created using the company’s Multi Matrix (MMX) technology, for the potential treatment of infectious diarrhea [ 810990 ], [ 810988 ]. In July 2007, positive data were reported from a phase II/III trial. At t..... . CSL-412 Originator: CSL Ltd. Highest Dev Status: Phase 2 Clinical. Updated on 06 July 2007. CSL is developing CSL-412, a vaccine using the company’s ISCOMATRIX proprietary adjuvant, aimed at the prevention or treatment of influenza in elderly patients; by May 2007, phase II trials were underway in the UK [ 804463 ]. CLINICAL DATA In May 2007, a double-blind, randomized, phase II study (NCT00479648; CSLCT-IIV-06-27) was initiated in subjects..... . ketoconazole isomer (FluidCrystal, metabolic syndrome), Camurus Originator: Camurus AB. Highest Dev Status: Phase 2 Clinical. Updated on 29 June 2007. Camurus and an undisclosed partner are developing a novel formulation of a ketoconazole isomer, presumably using the company’s controlled-release FluidCrystal technology, for the potential treatment of metabolic syndrome. By June 2007, phase II trials were underway [ 809513 ].. . TF-002 Originator: JADO Technologies GmbH. Highest Dev Status: Phase 2 Clinical. Updated on 04 July 2007. JADO is developing, TF-002, a topical mast-cell stabilizer, IgE blocker and histamine-release inhibitor, created using its raft intervention technology, for the potential treatment of allergies [ 810741 ]. In May 2007, a phase II trial for cutaneous mastocytosis began, with an allergy trial planned for later in 2007 [ 810828 ], [ 810741 ]. CLINICAL D..... . GW-273225 Originator: GlaxoSmithKline plc. Highest Dev Status: Phase 1 Clinical. Updated on 05 July 2007. GlaxoSmithKline is developing GW-273225 for the potential treatment of epilepsy and bipolar disorder. By November 2006, phase I studies were underway [ 809179 ]. CLINICAL DATA In January 2007, two grants for GW-273225 were active at the University of Southern Illinois for studies to evaluate the drug as a long-term therapy for seizure sufferers, an..... . ixabepilone (oral formulation), BMS Originator: Bristol-Myers Squibb Co. Highest Dev Status: Phase 1 Clinical. Updated on 06 July 2007. Bristol-Myers Squibb (BMS) is developing an oral formulation of ixabepilone (BMS-247550), a tubulin inhibitor and analog of epothilone B, for the potential treatment of cancer [ 769616 ]. Phase I trials of an oral enteric-coated formulation were initiated in April 2006 [ 811019 ]. A second phase I trial of oral ixabepilone was initiated in January 2007..... . JZP-7 Originator: Jazz Pharmaceuticals Inc. Highest Dev Status: Phase 1 Clinical. Updated on 04 July 2007. Jazz Pharmaceuticals is developing JZP-7, a once-daily formulation of a dopamine agonist, for the potential treatment of restless legs syndrome (RLS) [ 810249 ]. By March 2007, the drug was in phase I studies, with an additional pharmacokinetics study planned for 2007 [ 810215 ]. ADDITIONAL INFORMATION By April 2007, Jazz had formed an agreement with a..... . JZP-8 Originator: Jazz Pharmaceuticals Inc. Highest Dev Status: Phase 1 Clinical. Updated on 04 July 2007. Jazz Pharmaceuticals is developing JZP-8, a fast-release formulation of an undisclosed benzodiazepine, utilizing delivery technology licensed from an undisclosed partner, for the potential treatment of recurrent acute repetitive seizures in refractory epilepsy patients. By April 2007, a phase I study had been completed; at that time, Jazz expected to in..... . MKC-253 Originator: MannKind Corp. Highest Dev Status: Phase 1 Clinical. Updated on 04 July 2007. Mannkind is developing MKC-253, an dry powder inhaled formulation of a glucagon-like peptide-1 (GLP-1) using the company’s Technosphere technology, for the potential treatment of type 2 diabetes [ 804116 ]. CLINICAL DATA In May 2007, a single-dose, open-labelled, dose-ranging, phase Ia trial (NCT00475371; MKC-253-001; EudraCT Number 2007-000361-37) was..... . Nestorone + estradiol (transdermal spray, MDTS/ACROSS), Acrux Originator: Acrux Ltd. Highest Dev Status: Phase 1 Clinical. Updated on 05 July 2007. Acrux is developing a metered-dose transdermal spray (MDTS) formulation of Nestorone, a synthetic progestin similar to the natural hormone progesterone, in combination with estradiol, incorporating ACROSS skin penetration enhancers, for the potential use as a female contraceptive [ 810923 ]. In July 2007, positive phase I data were reported. At that time..... . Nestorone + ethinyl estradiol (transdermal spray, MDTS/ACROSS), Acrux Originator: Acrux Ltd. Highest Dev Status: Phase 1 Clinical. Updated on 05 July 2007. Acrux is developing a metered-dose transdermal spray (MDTS) formulation of Nestorone, a synthetic progestin similar to the natural hormone progesterone, in combination with the syntetic estrogen, ethinyl estradiol, incorporating ACROSS skin penetration enhancers, for the potential use as a female contraceptive [ 810923 ]. In July 2007, positive phase I d..... . SGLT-2 inhibitors (diabetes/obesity), Tanabe/Johnson & Johnson Originator: Tanabe Seiyaku Co Ltd. Highest Dev Status: Phase 1 Clinical. Updated on 05 July 2007. Tanabe , in collaboration with Johnson & Johnson (J&J), is developing a series of orally active sodium glucose cotransporter-2 (SGLT-2) inhibitors, for the potential treatment of type 2 diabetes and obesity [ 668285 ], [ 810872 ]. In June 2007, a lead compound had completed proof-of-concept and entered phase I trials; at that time, the compoun..... . ATL-801 Originator: Pennsylvania State University. Highest Dev Status: Discovery. Updated on 06 July 2007. Pennsylvania State University is investigating adenosine A2b receptor antagonists, including ATL-801 and BWA-1433 (structure shown), for the potential treatment of type II diabetes. In June 2007, preclinical studies were ongoing [ 808253 ]. PRECLINICAL DATA In June 2007, preclinical data on ATL-801 were presented at the 67th ADA Scientific Sessions i..... . BGC-20-0134 Originator: BTG plc. Highest Dev Status: Discovery. Updated on 06 July 2007. BTG is investigating BGC-20-0134, an immunomodulating structured lipid, for the potential treatment of multiple sclerosis (MS) [ 641358 ]. By March 2007, preclinical development was nearing completion and a phase I trial was planned to commence by April 2008 [ 799081 ]. PRECLINICAL DATA By December 2005, preclinical studies were underway [ 641358 ]. ..... . BGC-20-761 Originator: BTG plc. Highest Dev Status: Discovery. Updated on 06 July 2007. BTG is investigating BGC-20-761, a 5-HT 6 antagonist, for the potential treatment of schizophrenia [ 811024 ], [ 811111 ]. By September 2005, BTG was seeking to outlicense this program [ 811111 ]. PRECLINICAL DATA In March 2006, data were published that BGC-20-761 reverses scopolamine-induced impairment in an object recognition task in rats, which sugg..... . DRL-17564 Originator: Dr Reddy’s Laboratories Ltd. Highest Dev Status: Discovery. Updated on 03 July 2007. Dr Reddy’s Laboratories is investigating DRL-17564, a selective PPAR gamma modulator with potent PPAR alpha activity, for the potential treatment of type 2 diabetes [ 809573 ]. PRECLINICAL DATA In June 2007, preclinical data on DRL-17564 were published at the 67th ADA Scientific Sessions in Chicago, IL. When compared to rosiglitazone , DRL-17564 show..... . eNOS-upregulated bone-marrow-derived endothelial progenitor cells (myocardial infarction/ischemic heart disease), t2cure Originator: t2cure GmbH. Highest Dev Status: Discovery. Updated on 05 July 2007. t2cure , a company set up to develop therapies arising from research at Goethe University , is investigating t2c-007-eCHD, autologous bone-marrow-derived endothelial progenitor cells that have been treated with small molecules in vitro to stimulate endothelial nitric oxide synthase (eNOS) expression, for the potential treatment of acute myocardial infarc..... . GL-GP inhibitors (diabetes), Boehringer Ingelheim Originator: Boehringer Ingelheim Pharma KG. Highest Dev Status: Discovery. Updated on 05 July 2007. Boehringer Ingelheim is investigating GL-GP inhibitors, which inhibit the interaction between glycogen phosphorylase (GP) and the adaptor protein GL, for the potential treatment of type 2 diabetes [ 810391 ]. PRECLINICAL DATA In June 2007, preclinical data were presented on the effects of GL-GP inhibitors at the 67th ADA Scientific Sessions in Chi..... . glucokinase activators (oral, diabetes), Banyu Originator: Banyu Pharmaceutical Co Ltd. Highest Dev Status: Discovery. Updated on 06 July 2007. Banyu Pharmaceutical is investigating small molecule oral glucokinase activators for the potential treatment of type 2 diabetes [ 806101 ]. In June 2007, preclinical studies were ongoing [ 806101 ]. PRECLINICAL DATA In June 2007, preclinical data were presented on small molecule glucokinase activators at the 67th ADA Scientific Sessions in Chicago, IL..... |
回复此楼» 猜你喜欢
提取肿瘤组织消化后得到的肿瘤细胞死亡率过高
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有157人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
跪求一支AAV293细胞
已经有1人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
-
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
-
招收医学、基础医学类调剂研究生
已经有0人回复
-
是否属于脾肾阳虚证
已经有0人回复
|
. HBV vaccine (adjuvanted), Henogen Originator: Henogen SA. Highest Dev Status: Discovery. Updated on 04 July 2007. Henogen is investigating an adjuvanted vaccine for the potential prevention of HBV infection in immunocompromised subjects. In May 2007, a Czech phase III bioequivalence study was planned for September of that year [ 807913 ]. CLINICAL DATA In May 2007, the company was planning a phase III trial (NCT00480116, HN016HBV-002, 105759) in 450 healthy subjec..... . HM-571B Originator: Hanmi Pharmaceutical Co Ltd. Highest Dev Status: Discovery. Updated on 06 July 2007. Hanmi is investigating HM-571B, a multi-target kinase (MTK) inhibitor for the potential treatment of cancer [ 810791 ]. PRECLINICAL DATA Preclinical studies of HM-571B were initiated in 2006, and were ongoing in January 2007 [ 810791 ]. ADDITIONAL INFORMATION WO-2007055513 and WO-2007055514 , filed by Hanmi in November 2006, claim several quinazo..... . JZP-2 Originator: Jazz Pharmaceuticals Inc. Highest Dev Status: Discovery. Updated on 05 July 2007. Jazz Pharmaceuticals is investigating JZP-2, a fast-release formulation of an undisclosed benzodiazepine, for the potential treatment of panic attacks [ 810215 ]. By April 2007, a formulation had been identified, with clinical studies expected to start later in the year [ 810249 ].. . K-104 Originator: C&C Research Laboratories. Highest Dev Status: Discovery. Updated on 06 July 2007. C&C Research , a joint venture between Choongwae and Chugai , is investigating K-104, a platinum-based alkylating agent, for the potential treatment of cancer [ 809913 ]. By January 2007, preclinical data had been published showing that K-104 was more active than carboplatin and cisplatin against a panel of tumor cell lines. Mice administered a s..... . Kv1.5 voltage-gated potassium channel antagonists (atrial arrythmia), Merck & Co Originator: Merck & Co Inc. Highest Dev Status: Discovery. Updated on 06 July 2007. Merck & Co is investigating a series of Kv1.5 antagonists, as IKur ultrarapid delayed rectifier current blockers, for the potential treatment of atrial arrhythmia [ 810896 ]. By April 2004, preclinical studies had begun [ 810955 ]; these were ongoing in April 2007 [ 810896 ]. PRECLINICAL DATA In April 2007, preclinical data on the electrophys..... . NK1 antagonist (urinary incontinence), Takeda Originator: Takeda Pharmaceutical Co Ltd. Highest Dev Status: Discovery. Updated on 05 July 2007. Based on patent information, Takeda is believed to be investigating an NK1 antagonist for the potential treatment of urinary incontinence. By October 2006, the compound appeared to have been selected as a lead [ 809918 ]. PATENT INFORMATION WO-2006115285 and US-20060241145 describe, respectively, a process for the preparation of this compound and cr..... . Nov-206 Originator: Novacta Biosystems Ltd. Highest Dev Status: Discovery. Updated on 03 July 2007. Novacta Biosystems is investigating a series of recombinant lantibiotic-based proteins (Nov-206) for the potential treatment of bacterial skin infections. By July 2007, the program was in the lead optimization phase [ 810290 ]. ADDITIONAL INFORMATION In April 2007, Novacta published WO-2007036706 ??claiming mersacidin variants useful for treating bact..... . Nov-207 Originator: Novacta Biosystems Ltd. Highest Dev Status: Discovery. Updated on 03 July 2007. Novacta Biosystems is investigating the recombinant lantibiotic-based protein Nov-207 for the potential treatment of Clostridium difficile infection. By July 2007, it was in preclinical safety testing [ 810290 ].. . Nov-209 Originator: Novacta Biosystems Ltd. Highest Dev Status: Discovery. Updated on 03 July 2007. Novacta Biosystems is investigating a series of recombinant lantibiotic-based proteins (Nov-209) for the potential treatment of acne. By July 2007, the program was in the lead optimization phase [ 810290 ]. ADDITIONAL INFORMATION In April 2007, Novacta published WO-2007036706 ??claiming mersacidin variants useful for treating acne, amongst other indic..... . periocular insulin (hydrogel, diabetic retinopathy), Penn State Originator: Pennsylvania State University. Highest Dev Status: Discovery. Updated on 02 July 2007. Penn State is investigating periocular insulin delivered in a hydrogel for the potential treatment or prevention of diabetic retinopathy. By June 2007, the university had applied for intellectual property rights concerning this program [ 805357 ]. PRECLINICAL DATA In June 2007, preclinical data were presented at the 67th ADA Scientific Sessions in Chi..... . PO41-14-42-K1 Originator: Korea Institute of Oriental Medicine. Highest Dev Status: Discovery. Updated on 06 July 2007. Korea Institute of Oriental Medicine is investigating PO41-14-42-K1, a component of Pueraria Lobata which inhibits the formation of advanced glycation end products (AGEs) , for the potential prevention or treatment of diabetic cataract [ 807052 ]. PRECLINICAL DATA In June 2007, preclinical data were presented at the ADA’s 67th Scientific Sessions..... . PYC-38 Originator: Phylogica Ltd. Highest Dev Status: Discovery. Updated on 06 July 2007. Phylogica is investigating intranasal PYC-38, discovered using its propietary Phylomer technology, for the potential treatment of acute respiratory distress. Preclinical studies were underway by July 2007 [ 811107 ]. PRECLINICAL DATA By July 2007, PYC-38 had been shown to reduce lung inflammation in animal models of acute respiratory distress [ 811107 ..... . QGC-001 Originator: INSERM. Highest Dev Status: Discovery. Updated on 04 July 2007. Quantum Genomics , in collaboration with INSERM , is investigating QGC-001 for the potential treatment of hypertension [ 810758 ]. In June 2007, a phase I trial was expected to begin in 2008 [ 810758 ]. ADDITIONAL INFORMATION In June 2007, Quantum agreed a collaboration with INSERM [ 810758 ].. . SARS coronavirus spike glycoprotein antibodies (SARS), National Institutes of Health Originator: National Institutes of Health. Highest Dev Status: Discovery. Updated on 03 July 2007. The National Institutes of Health (NIH) is developing a series of injectable antibodies targeted to the receptor binding domain (RBD) of SARS virus spike glycoprotein, for the potential prophylaxis or treatment of SARS coronavirus infection. In July 2007, preclinical studies were ongoing [ 810420 ]. PRECLINICAL DATA In July 2007, preclinical data were..... . SKP-1032 Originator: SkyePharma plc. Highest Dev Status: Discovery. Updated on 29 June 2007. SkyePharma is investigating SKP-1032, an anti-inflammatory agent and analgesic for the potential treatment of pain and inflammation; by June 2007, preclinical studies were ongoing [ 809831 ]. At that time, the company was seeking to outlicense the drug [ 809831 ]. PRECLINICAL DATA By June 2007, the company listed SKP-1032 as undergoing preclinical “fea..... . SPC-3649 Originator: Santaris Pharma A/S. Highest Dev Status: Discovery. Updated on 05 July 2007. Santaris is investigating SPC-3649, a Locked Nucleic Acid (LNA)-based antagonist of miR-122, a liver-specific micro RNA (miRNA), for the potential treatment of hyperlipidemia and hepatitis C virus (HCV) infection [ 681762 ], [ 810961 ]. Preclinical studies were ongoing in July 2007 [ 810961 ]. PRECLINCIAL DATA By July 2007, dosing with SPC-3649 had be..... . V-0096 CR Originator: Orfagen. Highest Dev Status: Discovery. Updated on 03 July 2007. Orfagen is investigating V-0096 CR, a broad-spectrum external photoprotectant for the potential treatment of idiopathic solar urticaria [ 808124 ]. CLINICAL DATA In June 2007, a randomized, open-label, placebo-controlled, factorial assignment, phase II study (NCT00483496; V00096 CR 205 (ORF)) was planned in subjects with idiopathic solar urticaria in ..... . TTPABC Originator: TransTech Pharma Inc. Highest Dev Status: No Development Reported. Updated on 05 July 2007. TransTech was developing TTPABC, a small molecule with an undisclosed mechanism of action, for the potential treatment of diabetic complications including diabetic wounds and diabetic nephropathy. By March 2007, a phase I trial had been completed and the company was planning a phase II trial for diabetic nephropathy [ 811049 ]. However, the drug did not ..... . 来源: Thomson pharma |
2楼2007-07-10 09:13:01